Detalles de la búsqueda
1.
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
J Prev Alzheimers Dis
; 11(3): 537-548, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38706270
2.
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
J Prev Alzheimers Dis
; 10(1): 9-18, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36641605
3.
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report.
J Prev Alzheimers Dis
; 9(2): 231-235, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35542994
4.
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab.
J Prev Alzheimers Dis
; 8(1): 3-6, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33336218
5.
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.
J Prev Alzheimers Dis
; 8(3): 306-312, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34101788
6.
Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
J Prev Alzheimers Dis
; 8(2): 151-160, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569561
7.
Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease.
J Prev Alzheimers Dis
; 8(2): 175-180, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569564
8.
The Future of Anti-Amyloid Trials.
J Prev Alzheimers Dis
; 7(3): 146-151, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32463066
9.
Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease.
Dement Geriatr Cogn Disord
; 27(1): 69-75, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19145080
10.
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.
J Prev Alzheimers Dis
; 6(3): 169-173, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31062827
11.
Viewpoint: What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment?
J Prev Alzheimers Dis
; 10(3): 344-345, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37357269
12.
What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.
J Prev Alzheimers Dis
; 5(3): 171-174, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29972209
13.
Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia.
Dement Geriatr Cogn Disord
; 24(6): 476-82, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17992015
14.
Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech.
J Prev Alzheimers Dis
; 4(4): 264-272, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29181492
15.
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
J Prev Alzheimers Dis
; 4(2): 116-124, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29186281
16.
Realistic expectations for treatment success in Alzheimer's disease.
J Nutr Health Aging
; 10(5): 417-29, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17066215
17.
Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research.
J Prev Alzheimers Dis
; 8(4): 393-395, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34585210
18.
Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.
J Prev Alzheimers Dis
; 3(2): 114-120, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28459045
19.
Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.
J Prev Alzheimers Dis
; 3(2): 68-74, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-29210442
20.
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Arch Intern Med
; 158(9): 1021-31, 1998 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-9588436